Physician profile
Naima Zaheer
NPI 1447412192
$6,773.93
in general payments reported to CMS, 2019-2025
32 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.87 · 2021: $1,858 · 2022: $1,713 · 2023: $1,923 · 2024: $967 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $1,168.18 | 2021-2022 | |
| Viiv Healthcare Company | $813.18 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Abbvie INC. | $737.53 | 2021-2024 | Dalvance, Teflaro, Avycaz |
| Merck Sharp & Dohme LLC | $623.29 | 2021-2024 | Dificid, Pifeltro, Delstrigo |
| Melinta Therapeutics, LLC | $553.22 | 2021-2025 | Rezzayo, Vabomere, Kimyrsa |
| Glaxosmithkline, LLC. | $371.74 | 2022-2025 | Nucala |
| Gilead Sciences, INC. | $356.68 | 2021-2024 | Veklury |
| Regeneron Healthcare Solutions, INC. | $292.95 | 2022-2025 | Dupixent |
| Shionogi INC | $276.38 | 2021-2023 | Fetroja |
| Astellas Pharma US INC | $271.96 | 2022-2025 | Cresemba, Lexiscan |
| Foundation Medicine, INC. | $148.30 | 2021 | |
| La Jolla Pharmaceutical Company | $138.26 | 2021-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $117.89 | 2024 | Arcalyst |
| Insmed, INC. | $114.88 | 2024-2025 | Arikayce |
| Electromed, INC. | $109.08 | 2024-2025 | Smartvest |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $81.76 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $68.80 | 2021-2025 | Nuzyra |
| Tactile Systems Technology INC | $59.10 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $57.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.70 | 2022-2023 | Spiriva Respimat |
| Grifols USA, LLC | $54.20 | 2023-2024 | Prolastin-C Liquid |
| Baxter Healthcare | $49.85 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Janssen Biotech, INC. | $46.76 | 2023 | Symtuza |
| United Therapeutics Corporation | $33.43 | 2023 | Tyvaso |
| Smith+Nephew, INC. | $32.61 | 2022-2023 | Renasys Go V2 Home, Pico |
| Actelion Pharmaceuticals US, INC. | $27.86 | 2021 | |
| Napo Pharmaceuticals INC | $25.46 | 2023-2024 | Mytesi |
| Breas Medical, INC. | $23.61 | 2023 | Vivo 45 Ls |
| Viatris Specialty LLC | $19.72 | 2025 | Yupelri |
| Convatec INC. | $17.31 | 2022 | |
| Pfizer INC. | $14.65 | 2023 | |
| Allergan, INC. | $11.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naima Zaheer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.